Zilucoplan PLGA Sustained Release Formulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic complement inhibitors require frequent intravenous or subcutaneous administration, which burdens patients and reduces quality of life, highlighting the need for less burdensome administration methods to modulate complement activity effectively.
Innovation Solution
A sustained release formulation incorporating a C5 inhibitory cyclic polypeptide, such as zilucoplan, combined with a poly lactic-co-glycolic acid (PLGA) matrix, providing a controlled release profile that maintains effective concentrations over an extended period, potentially reducing administration frequency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If frequent intravenous or subcutaneous administration is used to deliver complement inhibitors, then therapeutic effectiveness is maintained, but patient burden increases and quality of life decreases
Solution Approach 1:
The invention incorporates the complement inhibitor into a sustained-release formulation (such as lipid nanoparticles, polymeric micelles, or hydrogels) that is administered in advance and continuously releases the therapeutic agent over an extended period. This preliminary action eliminates the need for frequent re-administration while maintaining therapeutic effectiveness, directly resolving the contradiction between reliable therapy and patient convenience
2Ease of operation
If sustained release formulation is used to reduce administration frequency, then patient burden decreases, but formulation complexity increases
Solution Approach 1:
The invention modifies the physical and chemical parameters of the complement inhibitor by formulating it into sustained-release systems with specific characteristics (particle size, composition, release kinetics). By changing these parameters, the formulation achieves extended release without requiring complex delivery devices or invasive procedures, thus reducing administration frequency while keeping the formulation manageable
Solution Approach 2:
The invention uses composite material systems such as lipid-polymer hybrid nanoparticles or polymeric micelles that combine multiple materials with complementary properties. These composite formulations provide both sustained release capability and biocompatibility, achieving reduced administration frequency without excessive complexity
3Reliability
If high concentration of complement inhibitor is administered to ensure therapeutic levels, then treatment effectiveness improves, but initial burst release increases causing potential toxicity
Solution Approach 1:
The invention employs porous matrix materials (such as porous lipids or polymeric matrices) that encapsulate the complement inhibitor. The porous structure provides controlled diffusion pathways that prevent rapid burst release while ensuring sustained release of therapeutic levels over time, thus maintaining effectiveness without initial toxicity
Solution Approach 2:
The invention creates formulations with heterogeneous structures where different regions have different properties - the core or inner regions provide sustained release at controlled rates, while the outer regions or surface modifications prevent premature release. This local quality differentiation ensures therapeutic levels are maintained without dangerous initial burst
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves a sustained release of zilucoplan, minimizing initial burst and maintaining therapeutic levels for up to three weeks, thereby reducing hemolysis and treating complement-related indications with less frequent dosing.
Implementation Method 1
The formulation achieves a sustained release of zilucoplan, minimizing initial burst and maintaining therapeutic levels for up to three weeks
Implementation Method 2
A sustained release formulation incorporating a C5 inhibitory cyclic polypeptide, such as zilucoplan, combined with a poly lactic-co-glycolic acid (PLGA) matrix
Data Source
AI summary
Embodiments of the disclosure provide sustained release formulations that include active ingredients and release modulating matrices. Also provided are related methods of preparation and methods of addressing therapeutic indications with sustained release formulations described herein. Included are sustained release formulations with complement inhibitors (e.g., C5 inhibitory cyclic polypeptides, zilucoplan, and/or active metabolites or variants thereof) for treating complement-related indications.